Updating results

Rehabilitation in adults with complex psychosis and related severe mental health conditions

In development [GID-NG10092] Expected publication date: 19 June 2020

NICE guideline In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Flu vaccination: increasing uptake

In development [GID-QS10071] Expected publication date: 09 January 2020

Quality standard In development

Rheumatoid arthritis in over 16s (QS update)

In development [GID-QS10136] Expected publication date: 09 January 2020

Quality standard In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Cyanoacrylate glue occlusion for varicose veins

In development [GID-IPG10128] Expected publication date: 26 February 2020

Interventional procedures guidance In development

Bilateral cervicosacropexy or vaginosacropexy using mesh for pelvic organ prolapse

In development [GID-IPG10123] Expected publication date: 26 February 2020

Interventional procedures guidance In development

MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy

In development [GID-IPG10122] Expected publication date: 26 February 2020

Interventional procedures guidance In development

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

NICE guideline In development

Inducing labour (Update)

In development [GID-NG10082] Expected publication date: 01 July 2020

NICE guideline In development

Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 26 August 2021

NICE guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

In development [GID-TA10186] Expected publication date: 08 January 2020

Technology appraisal guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: 08 September 2020

Highly specialised technologies guidance In development

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

In development [GID-TA10221] Expected publication date: TBC

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Medical technologies guidance In development

Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347

In development [GID-TA10264] Expected publication date: TBC

Technology appraisal guidance In development

Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids

In development [GID-IPG10147] Expected publication date: TBC

Interventional procedures guidance In development

Permanent His-bundle pacemaker implantation for heart failure

In development [GID-IPG10145] Expected publication date: TBC

Interventional procedures guidance In development

Repetitive short pulse transscleral cyclophotocoagulation for glaucoma

In development [GID-IPG10148] Expected publication date: TBC

Interventional procedures guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction

In development [GID-DG10035] Expected publication date: 26 August 2020

Diagnostics guidance In development

Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)

In development [GID-TA10233] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

In development [GID-TA10234] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Technology appraisal guidance In development

Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

In development [GID-IPG10067] Expected publication date: TBC

Interventional procedures guidance In development

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Avelumab for untreated PD-L1 positive non-small-cell lung cancer [ID1261]

In development [GID-TA10250] Expected publication date: TBC

Technology appraisal guidance In development

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Technology appraisal guidance In development

Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

In development [GID-TA10248] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

In development [GID-TA10242] Expected publication date: TBC

Technology appraisal guidance In development

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Technology appraisal guidance In development

Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Technology appraisal guidance In development

Recombinant human parathyroid hormone for treating hypoparathyroidism [1094]

In development [GID-TA10219] Expected publication date: TBC

Technology appraisal guidance In development

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development